U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H11NO3
Molecular Weight 193.1992
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BETAMIPRON

SMILES

OC(=O)CCNC(=O)C1=CC=CC=C1

InChI

InChIKey=CWXYHOHYCJXYFQ-UHFFFAOYSA-N
InChI=1S/C10H11NO3/c12-9(13)6-7-11-10(14)8-4-2-1-3-5-8/h1-5H,6-7H2,(H,11,14)(H,12,13)

HIDE SMILES / InChI

Description

Betamipron (BP) is an amino acid derivative that has benzoyl and carboxyl groups in its structure, and it also has very low toxicity in mammals (LD50 in the rat, more than 3,000 mg/kg, i.v.). BP is a renal anionic transport inhibitor and decreases nephrotoxicity caused by high doses of carbapenems, anionic drugs, by inhibiting the drug accumulation in the renal cortex. BP significantly inhibited organic anion uptake by human organic anion transporter 1 (human-OAT1) and human-OAT3 in a dose-dependent manner. Panipenem-betamipron is marketed as Carbenin® (Sankyo Company, Tokyo, Japan).

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
23.6 µM [Ki]
48.3 µM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
Carbenin

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
Intravenous drip infusion of either 10 mg/10 mg/kg or 20 mg/20 mg/kg of Panipenem/betamipron (PAPM/BP) for 30 minutes.
Route of Administration: Intravenous
In Vitro Use Guide
S2 hOAT2 cells were incubated in a medium containing 50 nM [3H]PGF2  at 37C for 2 min in the absence or presence of 1 mM betamipron, and the effect of the drug in PGF2 uptaked was studied. Inhibition of ES uptake by hOAT4 was measured at 500 uM of the drug.